Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02922413 · ClinicalTrials.gov registry record · Phase 2
Panhematin for Prevention of Acute Attacks of Porphyria
A Phase 2 study, sponsored by The University of Texas Medical Branch, Galveston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02922413 is a Phase 2 study that was terminated before completion, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 13 participants.
The verdict
NCT02922413, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Medical Branch, Galveston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Panhematin is safe and effective for prevention of acute attacks of porphyria. The study aims to provide high quality evidence for the use on hemin for prevention of acute attacks of porphyria. High quality studies have not been done previously for treating or preventing acute attacks with hemin. The lack of strong evidence for efficacy of hemin for treatment and prevention of attacks limits its availability for patients with acute porphyrias. Funding source: FDA Office of Orphan Product Development (FDA OOPD) FD-R-03720
Interventions
- OTHER Placebo
- BIOLOGICAL Hemin for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-10-30 |
| Est. Completion | 2023-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02922413
The ClinicalTrials.gov registry entry for NCT02922413 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02922413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02922413 about?
NCT02922413 is a clinical study titled "Panhematin for Prevention of Acute Attacks of Porphyria". The purpose of this study is to determine if Panhematin is safe and effective for prevention of acute attacks of porphyria. The study aims to provide high quality evidence for the use on hemin for prevention of acute attacks of porphyria. High quality studies have not been done previously for treat...
What is the current status of trial NCT02922413?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2015-10-30. Estimated completion is 2023-12-27.
What interventions are being tested in trial NCT02922413?
The interventions under investigation include: Placebo (OTHER), Hemin for injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT02922413?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.